Table 5.

Directed antimicrobial agents stratified by type of infection

Directed antimicrobial therapy	Number (%) of patients
	Infection type
	VABP (N = 31)	Bacteremia (N = 22)	cUTI/AP (N = 18)	HABP (N = 16)	SWI (N = 16)	BTI (N = 9)	DWI (N = 7)	SBFI (N = 5)	All (N = 124)
No treatment	2 (6.5%)	1 (4.5%)	1 (5.6%)	1 (6.3%)	3 (18.8%)	1 (11.1%)	1 (14.3%)	0	10 (8.1%)
No Gram-negative coverage	0	0	0	0	1 (6.3%)	0	1 (14.3%)	0	2 (1.6%)
Gram-negative therapy	29 (93.5%)	21 (95.5%)	17 (94.4%)	15 (93.8%)	12 (75.0%)	8 (88.9%)	5 (71.4%)	5 (100%)	112 (90.3%)
Monotherapy	3 (9.7%)	1 (4.5%)	12 (66.7%)	5 (31.3%)	6 (37.5%)	2 (22.2%)	1 (14.3%)	1 (20.0%)	31 (25.0%)
Dual therapy	13 (41.9%)	8 (36.4%)	5 (27.8%)	8 (50.0%)	6 (37.5%)	5 (55.6%)	3 (42.9%)	2 (40.0%)	50 (40.3%)
Three drug combinations	10 (32.3%)	10 (45.5%)	0	2 (12.5%)	0	1 (11.1%)	1 (14.3%)	2 (40.0%)	26 (21.0%)
Four and more drug combinations	3 (9.7%)	2 (9.1%)	0	0	0	0	0	0	5 (4.0%)
Number active agents
No active agent	3 (9.7%)	3 (13.6%)	1 (5.6%)	2 (12.5%)	1 (6.3%)	0	1 (14.3%)	0	11 (8.9%)
One active agent	16 (51.6%)	12 (54.5%)	15 (83.3%)	10 (62.5%)	8 (50.0%)	4 (44.4%)	3 (42.9%)	3 (60.0%)	71 (57.3%)
Two active agents	9 (29.0%)	4 (18.2%)	1 (5.6%)	3 (18.8%)	3 (18.8%)	4 (44.4%)	1 (14.3%)	2 (40.0%)	27 (21.8%)
Three active agents	1 (3.2%)	1 (4.5%)	0	0	0	0	0	0	2 (1.6%)
Four active agents	0	1 (4.5%)	0	0	0	0	0	0	1 (0.8%)

AP acute pyelonephritis, BTI biliary tract infection, cUTI complicated urinary tract infection, DWI deep wound infection, HABP hospital-acquired bacterial pneumonia, SBFI sterile body fluids infection, SWI superficial wound infection, VABP ventilator-associated bacterial pneumonia